Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gastrointestinal cancer].

Yasushi Omuro1, Tsuneo Sasaki

  • 1Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.

Journal of gastrointestinal cancer·2023
Same author

[In Commemoration of the 50th Anniversary of Gan To Kagaku Ryoho].

Gan to kagaku ryoho. Cancer & chemotherapy·2023
Same author

[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2022
Same author

Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.

Cancer science·2022
Same author

Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study.

BMC cancer·2022
Same author

Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma.

Medicine·2022
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Nonmyeloablative allogeneic stem-cell transplantation (NST) is feasible for refractory gastrointestinal cancer. While graft-versus-tumor effects were observed, outcomes were limited in highly progressive disease.

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Context:

  • Refractory gastrointestinal cancers present significant treatment challenges.
  • Allogeneic stem-cell transplantation offers potential therapeutic avenues.
  • Nonmyeloablative conditioning regimens aim to reduce toxicity.

Purpose:

  • To evaluate the feasibility and efficacy of nonmyeloablative allogeneic stem-cell transplantation (NST) in patients with refractory gastrointestinal cancer.
  • To assess graft-versus-host disease (GVHD) incidence and severity.
  • To investigate graft-versus-tumor (GVT) effects and clinical responses.

Summary:

  • Ten patients with refractory gastrointestinal cancer underwent HLA-identical sibling NST with cyclophosphamide and fludarabine conditioning.
  • All patients engrafted successfully; 5 developed acute GVHD and 5 developed chronic GVHD.

Related Experiment Videos

  • Three patients showed tumor marker regressions (GVT effect), one had a partial response, and three had stable disease. Survival was limited due to progressive disease.

    • Impact:

    • NST is a feasible approach for refractory gastrointestinal cancer.
    • Demonstrates the potential for GVT effects in gastrointestinal malignancies.
    • Highlights the need for strategies to overcome limited efficacy in highly progressive disease.